NLS Pharmaceutics, which is developing controlled-release formulations of approved drugs for ADHD and narcolepsy, raised $20 million by offering 4.8 million units at $4.15, below the range of $5 to $6. The company offered 1.2 million more units than...read more
NLS Pharmaceutics, which is developing controlled-release formulations of approved drugs for ADHD and narcolepsy, announced terms for its IPO on Monday.
The Stans, Switzerland-based company plans to raise $20 million by offering 3.6 million units at a price...read more
There are no IPOs scheduled for the week ahead.
The most likely April IPOs
Despite the encouraging market rally this past week, the Renaissance IPO Volatility Index is still about double the five-year average and few companies have filed,...read more
Following the IPO Index’s sharpest drop ever recorded, one cannabis SPAC is keeping the IPO market alive, expected to raise $150 million in the week ahead. Social Capital’s latest SPACs (IPOB.U, IPOC.U) are also eligible to price this week. ...read more
Micro-cap CNS drug developer NLS Pharmaceutics prices IPO at $4.15, below the range
NLS Pharmaceutics, which is developing controlled-release formulations of approved drugs for ADHD and narcolepsy, raised $20 million by offering 4.8 million units at $4.15, below the range of $5 to $6. The company offered 1.2 million more units than...read more
Micro-cap CNS drug developer NLS Pharmaceutics sets terms for $20 million IPO
NLS Pharmaceutics, which is developing controlled-release formulations of approved drugs for ADHD and narcolepsy, announced terms for its IPO on Monday. The Stans, Switzerland-based company plans to raise $20 million by offering 3.6 million units at a price...read more
US IPO Week Ahead: An empty calendar and a quiet week for the IPO market
There are no IPOs scheduled for the week ahead. The most likely April IPOs Despite the encouraging market rally this past week, the Renaissance IPO Volatility Index is still about double the five-year average and few companies have filed,...read more
US IPO Week Ahead: 1 cannabis SPAC lights up a dim IPO market
Following the IPO Index’s sharpest drop ever recorded, one cannabis SPAC is keeping the IPO market alive, expected to raise $150 million in the week ahead. Social Capital’s latest SPACs (IPOB.U, IPOC.U) are also eligible to price this week. ...read more